Page last updated: 2024-08-05 11:13:46
primary arylamine
A primary amine formally derived from ammonia by replacing one hydrogen atom by an aryl group. R-NH2 where R is an aryl group.
ChEBI ID: 50471
Members (16)
| Member | Definition | Role |
|---|---|---|
| 1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine | A N-arylpiperazine that is piperazine substituted by 2-(4-aminophenyl)ethyl and 3-(trifluoromethyl)phenyl groups at positions 1 and 4, respectively. It is a selective 5-HT1A serotonin receptor agonist and 5-HT1D serotonin receptor antagonist. | LY-165163 |
| 2-(1H-benzimidazol-2-yl)aniline | A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a 2-aminophenyl group at position 2. | 2-(1H-benzimidazol-2-yl)aniline |
| 2-fluoroaniline | A derivative of aniline in which the hydrogen at position 2 has been substituted by fluorine. It is used as a pharmaceutical intermediate | 2-fluoroaniline |
| 2,4-xylidine | A primary arylamine that is aniline in which the hydrogens at the 2- and 4-positions are replaced by methyl groups. A clear to yellow liquid, it is used in production of certain dyes, pesticides and other chemicals. | 2,4-dimethylaniline |
| 2,5-xylidene | A primary arylamine that is aniline in which the hydrogens at the 2- and 5-positions are replaced by methyl groups. It is used in the manufacture of dyes and other chemicals. | 2,5-dimethylaniline |
| 2,6-xylidine | A primary arylamine that is aniline in which the hydrogens at the 2- and 6-positions are replaced by methyl groups. It is used in the production of some anasthetics and other chemicals. It is a drug metabolite of lidocaine (local anasthetic). | 2,6-dimethylaniline |
| 3-fluoroaniline | A derivative of aniline in which the hydrogen at position 3 has been substituted by fluorine. It is used as a pharmaceutical intermediate. | 3-fluoroaniline |
| 3,4-xylidine | A primary arylamine that is aniline in which the hydrogens at the 3- and 4-positions are replaced by methyl groups. A low-melting, crystalline solid, it is used in the production of vitamin B2, dyes, pesticides and other chemicals. | 3,4-dimethylaniline |
| 4-fluoroaniline | A primary arylamine that is the derivative of aniline in which the hydrogen at position 4 has been substituted by fluorine. It is used as an intermediate in the manufacture of pharmaceuticals, herbicides and plant growth regulators. | 4-fluoroaniline |
| amezinium | A pyridazinium ion that is pyridazin-1-ium which is substituted by a phenyl, amino and methoxy groups at positions 1, 4 and 6, respectively. | amezinium |
| aniline | A primary arylamine in which an amino functional group is substituted for one of the benzene hydrogens. | aniline |
| clenbuterol | A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group. | clenbuterol |
| disperse orange 3 | Azobenzene substituted at the phenyl 4-positions by an amino and a nitro group. | 4-(4-nitrophenylazo)aniline |
| ferrostatin-1 | An ethyl ester resulting from the formal condensation of the carboxy group of 3-amino-4-(cyclohexylamino)benzoic acid with ethanol. It is a potent inhibitor of ferroptosis, a distinct non-apoptotic form of cell death caused by lipid peroxidation. It is also a radical-trapping antioxidant and has the ability to reduce the accumulation of lipid peroxides and chain-carrying peroxyl radicals. | ferrostatin-1 |
| lamotrigine | A member of the class of 1,2,4-triazines in which the triazene skeleton is substituted by amino groups at positions 3 and 5, and by a 2,3-dichlorophenyl group at position 6. | lamotrigine |
| pd 166866 | A member of the class of pyridopyrimidines that is pyrido[2,3-d]pyrimidine substituted by an amino group at position 2, 3,5-dimethoxyphenyl group at position 6, and by a (tert-butylcarbamoyl)nitrilo group at position 7. It is a selective ATP competitive inhibitor of the human fibroblast growth factor-1 receptor (FGFR1) tyrosine kinase with an IC50 of 52.4 nM. | PD-166866 |
Research
Studies (7,274)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 926 (12.73) | 18.7374 |
| 1990's | 1,228 (16.88) | 18.2507 |
| 2000's | 2,183 (30.01) | 29.6817 |
| 2010's | 2,218 (30.49) | 24.3611 |
| 2020's | 719 (9.88) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 605 (7.81%) | 5.53% |
| Reviews | 695 (8.97%) | 6.00% |
| Case Studies | 773 (9.97%) | 4.05% |
| Observational | 42 (0.54%) | 0.25% |
| Other | 5,636 (72.71%) | 84.16% |